Commitments and Contingencies Commitments and Contingencies (Tables)

12 Months Ended

Dec. 31, 2012

Commitments and Contingencies Disclosure [Abstract]

Recorded Unconditional Purchase Obligations [Table Text Block]

Future estimated contractual obligations as of December 31, 2012 are:



Contractual Obligations ⁽¹⁾	2013		2014		2015		2016		2017		Later Years		Total
	(In thousands)
Inventory related commitments	$	40,753	$	28,468	$	8,210	$	710	$	—	$	—	$	78,141
Long-term debt obligations	3,781		3,781		3,781		3,781		276,891		—		292,015
Research and development	6,266		780		—		—		—		—		7,046
Operating leases	7,412		6,172		5,645		5,378		11,690		18,526		54,823
Selling, general and administrative	2,550		850		139		—		—		—		3,539
Total contractual obligations	$	60,762	$	40,051	$	17,775	$	9,869	$	288,581	$	18,526	$	435,564


(1)	This table does not include any milestone and royalty payments which may become payable to third-parties for which the timing and likelihood of such payments are not known, as discussed below.

All of the inventory related commitments included above are non-cancellable. Included within the inventory related commitments above are purchase commitments totaling $29.9 million for 2013, $26.6 million for 2014 and $7.5 million for 2015 for Angiomax bulk drug substance. Of the total estimated contractual obligations for research and development and selling, general and administrative activities,

- Definition

Tabular disclosure of unconditional purchase obligations that are recognized as a liability on the balance sheet, including the nature and term of the unconditional purchase obligations; the aggregate amount of payments for each of the five years following the date of the latest balance sheet; and the combined aggregate amount of maturities and sinking fund requirements for all long-term borrowings associated with suppliers' financing arrangements.

+ References+ Details